He graduated from the Department of Biochemistry at the University of Dundee (1996) and was a Post-Doctoral Fellow at the Dana-Farber Cancer Institute and Harvard Medical School. In 2001 he started his own lab at the MRC Cancer Cell Unit at the University of Cambridge, developing the Peptide Aptamer technology that would be the foundation for his first spin-out company, Aptuscan, which was acquired by Avacta Group plc in 2012. He was a Senior Lecturer and Visiting Professor at the Leeds Institute of Molecular Medicine, and a Visiting Member of the Astbury Centre for Structural Molecular Biology. In addition to Aptuscan he has founded, co-founded or led 3 other startups before co-founding éclateral Ltd in 2021, with a mission to move routine testing for chronic conditions out of hospitals and into patients' homes. His work on combining biology and electronics was recognised by a Nano Top 50 award from NASA Tech Briefs, jointly with Christoph Wälti and Giles Davies for "a development that is likely to have the greatest impact on nanotechnology" in 2008.